Alogliptin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Alogliptin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 28: Line 28:
{{CMG}}
{{CMG}}


{{EH}}
 


'''Alogliptin''' (codenamed '''SYR-322''') is an investigational [[anti-diabetic drug]] in the [[DPP-4 inhibitors|DPP-4 inhibitor]] class,<ref name="pmid17441705">{{cite journal |author=Feng J, Zhang Z, Wallace MB, ''et al'' |title=Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV |journal=[[J. Med. Chem.]] |volume=50 |issue=10 |pages=2297–300 |year=2007 |pmid=17441705 |doi=10.1021/jm070104l |url=http://dx.doi.org/10.1021/jm070104l}}</ref> being developed by [[Takeda Pharmaceutical Company]]. Takeda has submitted a [[New Drug Application]] for alogliptin to the U.S. [[Food and Drug Administration]], after positive results from [[clinical trial#Phase III|Phase III]] [[clinical trial]]s.<Ref>{{cite press release | url = http://www.takeda.com/press/article_28864.html | title = Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | date = [[January 4]] [[2008]] | accessdate = 2008-01-09 | publisher = [[Takeda Pharmaceutical Company]]}}</ref>
'''Alogliptin''' (codenamed '''SYR-322''') is an investigational [[anti-diabetic drug]] in the [[DPP-4 inhibitors|DPP-4 inhibitor]] class,<ref name="pmid17441705">{{cite journal |author=Feng J, Zhang Z, Wallace MB, ''et al'' |title=Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV |journal=[[J. Med. Chem.]] |volume=50 |issue=10 |pages=2297–300 |year=2007 |pmid=17441705 |doi=10.1021/jm070104l |url=http://dx.doi.org/10.1021/jm070104l}}</ref> being developed by [[Takeda Pharmaceutical Company]]. Takeda has submitted a [[New Drug Application]] for alogliptin to the U.S. [[Food and Drug Administration]], after positive results from [[clinical trial#Phase III|Phase III]] [[clinical trial]]s.<Ref>{{cite press release | url = http://www.takeda.com/press/article_28864.html | title = Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | date = [[January 4]] [[2008]] | accessdate = 2008-01-09 | publisher = [[Takeda Pharmaceutical Company]]}}</ref>

Revision as of 20:54, 8 August 2012

Alogliptin
File:Alogliptin.svg
Clinical data
Routes of
administration		Oral
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H21N5O2
Molar mass339.39 g/mol
3D model (JSmol)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class,[1] being developed by Takeda Pharmaceutical Company. Takeda has submitted a New Drug Application for alogliptin to the U.S. Food and Drug Administration, after positive results from Phase III clinical trials.[2]

References

  1. ↑ Feng J, Zhang Z, Wallace MB; et al. (2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". J. Med. Chem. 50 (10): 2297–300. doi:10.1021/jm070104l. PMID 17441705.
  2. ↑ "Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S." (Press release). Takeda Pharmaceutical Company. January 4 2008. Retrieved 2008-01-09. Check date values in: |date= (help)

Template:Pharma-stub Template:Oral hypoglycemics

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Alogliptin&oldid=668131"